In the BioHarmony Drug Report Database

"Preview" Icon

Cabozantinib

Cabometyx, Cometriq (cabozantinib) is a small molecule pharmaceutical. Cabozantinib was first approved as Cabometyx on 2012-11-29. It is used to treat renal cell carcinoma in the USA. It has been approved in Europe to treat hepatocellular carcinoma, renal cell carcinoma, and thyroid neoplasms. The pharmaceutical is active against hepatocyte growth factor receptor and vascular endothelial growth factor receptor 2. In addition, it is known to target proto-oncogene tyrosine-protein kinase receptor Ret. Cometriq’s patents are valid until 2033-07-09 (FDA).

 

Trade Name

 

Cabometyx, Cometriq
 

Common Name

 

cabozantinib
 

ChEMBL ID

 

CHEMBL2105717
 

Indication

 

hepatocellular carcinoma, renal cell carcinoma, thyroid neoplasms
 

Drug Class

 

Tyrosine kinase inhibitors

Image (chem structure or protein)

Cabozantinib structure rendering